Details for Patent: 9,180,091
Which drugs does patent 9,180,091 protect, and when does it expire?
Patent 9,180,091 protects IMVEXXY and is included in one NDA.
This patent has one hundred and sixty-seven patent family members in twenty-one countries.
Summary for Patent: 9,180,091
| Title: | Soluble estradiol capsule for vaginal insertion |
| Abstract: | According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy. |
| Inventor(s): | Brian A. Bernick, Julia M. Amadio, Peter H. R. Persicaner, Neda Irani, Janice Louise Cacace, Thorsteinn Thorsteinsson, Frederick D. Sancilio |
| Assignee: | TherapeuticsMD Inc |
| Application Number: | US14/136,048 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,180,091 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,180,091
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-001 | May 29, 2018 | AB | RX | Yes | Yes | 9,180,091 | ⤷ Start Trial | Y | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY | ⤷ Start Trial | ||
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-001 | May 29, 2018 | AB | RX | Yes | Yes | 9,180,091 | ⤷ Start Trial | Y | TREATMENT OF DYSPAREUNIA | ⤷ Start Trial | ||
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-002 | May 29, 2018 | AB | RX | Yes | Yes | 9,180,091 | ⤷ Start Trial | Y | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY | ⤷ Start Trial | ||
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-002 | May 29, 2018 | AB | RX | Yes | Yes | 9,180,091 | ⤷ Start Trial | Y | TREATMENT OF DYSPAREUNIA | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,180,091
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2782584 | ⤷ Start Trial | 301153 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | 2021C/558 | Belgium | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | 122021000080 | Germany | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | LUC00245 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | 132021000000197 | Italy | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | C202130068 | Spain | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | 21C1058 | France | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
